Ann Neurol

1. KLUGE A, Borsche M, Streubel-Gallasch L, Gul T, et al
   alpha-Synuclein Pathology in PRKN-Linked Parkinson's Disease: New Insights from a Blood-Based Seed Amplification Assay.
   Ann Neurol. 2024 Mar 28. doi: 10.1002/ana.26917.
   

   >> Share

   
   

   
   Exp Brain Res

2. FROUNI I, Kim E, Shaqfah J, Bedard D, et al
   [(3)H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain.
   Exp Brain Res. 2024 Mar 25. doi: 10.1007/s00221-024-06815.
   

   >> Share

   
   
3. MACDONALD HJ, Ruitenberg MFL
   Dopamine system involvement in impulse control.
   Exp Brain Res. 2024;242:781-782.
   

   >> Share

   
   

   
   J Neural Transm (Vienna)

4. HE G, Ren J, Shi H, Liu W, et al
   Correlation between the MNCD classification-based staging of Parkinson's disease and quality of life: a cross-sectional study.
   J Neural Transm (Vienna). 2024 Mar 28. doi: 10.1007/s00702-024-02756.
   

   >> Share

   
   

   
   J Neurochem

5. NETZAHUALCOYOTZI C, Santillan-Cigales JJ, Adalid-Peralta LV, Velasco I, et al
   Infiltration of immune cells to the brain and its relation to the pathogenesis of Alzheimer's and Parkinson's diseases.
   J Neurochem. 2024 Mar 29. doi: 10.1111/jnc.16106.
   

   >> Share

   
   

   
   J Neurol Neurosurg Psychiatry

6. KIM R, Choi S, Kang N, Park K, et al
   Effects of high-intensity interval training and moderate-intensity continuous training on non-motor symptoms in patients with Parkinson's disease: a randomised pilot trial.
   J Neurol Neurosurg Psychiatry. 2024 Mar 28:jnnp-2023-331990.
   

   >> Share

   
   

   
   Mov Disord

7. KAMATH SD, Holla VV, Phulpagar P, Kamble N, et al
   Clinicogenetic Characterization of Patients with PD and Heterozygous GBA1 Variants in an Indian Cohort.
   Mov Disord. 2024;39:628-630.
   

   >> Share

   
   
8. MUNCHAU A, Klein C, Beste C
   Rethinking Movement Disorders.
   Mov Disord. 2024;39:472-484.
   

   >> Share

   
   
9. THOMSEN M, Marth K, Loens S, Everding J, et al
   Large-Scale Screening: Phenotypic and Mutational Spectrum in Isolated and Combined Dystonia Genes.
   Mov Disord. 2024;39:526-538.
   

   >> Share

   
   
10. LEWITT PA, Stebbins GT, Christensen KV, Tan R, et al
    Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.
    Mov Disord. 2024;39:613-618.
    

    >> Share

    
    
11. BINGHAM CS, McIntyre CC
    Coupled Activation of the Hyperdirect and Cerebellothalamic Pathways with Zona Incerta Deep Brain Stimulation.
    Mov Disord. 2024;39:539-545.
    

    >> Share

    
    
12. DING H, Nasseroleslami B, Mirzac D, Isaias IU, et al
    Re-emergent Tremor in Parkinson's Disease: Evidence of Pathologic beta and Prokinetic gamma Activity.
    Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29771.
    

    >> Share

    
    
13. VERONESE N, Nova A, Fazia T, Riggi E, et al
    Contribution of Nutritional, Lifestyle, and Metabolic Risk Factors to Parkinson's Disease.
    Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29778.
    

    >> Share

    
    

    
    Neurobiol Dis

14. IOVINO L, Vander Zwaag J, Kaur G, Khakpour M, et al
    Investigation of microglial diversity in a LRRK2 G2019S mouse model of Parkinson's disease.
    Neurobiol Dis. 2024 Mar 23:106481. doi: 10.1016/j.nbd.2024.106481.
    

    >> Share

    
    
15. JIAO LL, Dong HL, Liu MM, Wu PL, et al
    The potential roles of salivary biomarkers in neurodegenerative diseases.
    Neurobiol Dis. 2024;193:106442.
    

    >> Share

    
    

    
    Neuroscience

16. SALLY SAMSON J, Ramesh A, Deepa Parvathi V
    Development of midbrain dopaminergic neurons and the advantage of using hiPSCs as a model system to study Parkinson's disease.
    Neuroscience. 2024 Mar 22:S0306-4522(24)00138.
    

    >> Share

    
    

    
    Science

17. NORMILE D
    Transgenic marmosets mimic Parkinson's symptoms.
    Science. 2024;383:1402.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share